EC Number   |
Application |
Reference |
|---|
    2.5.1.18 | analysis |
acetylcholinesterase and glutathione S-transferase activities in Daphnia magna are used in the standardized Daphnia magna immobility toxicity test for toxic substances e.g. in water quality monitoring, overview |
673173 |
| 2.5.1.18 | analysis |
immobilized GST mutant Gln53Ala is used to assemble a biosensor for malathion |
702782 |
| 2.5.1.18 | biotechnology |
commercial fusion partner using for enhancing the solubility of recombinant proteins |
691484 |
| 2.5.1.18 | drug development |
glutathione S-transferases of Plasmodium parasites are potential targets for antimalarial drug and vaccine development |
701917 |
| 2.5.1.18 | drug development |
the enzyme is a target for development of irreversible GST inhibitors as anticancer agents based on prostaglandins |
671615 |
| 2.5.1.18 | drug development |
the enzyme is a target for drug development against the parasite |
673492 |
| 2.5.1.18 | drug development |
the enzyme is a target for inhibitor design |
671078 |
| 2.5.1.18 | drug development |
the enzyme is a target for structure-based drug/inhibitor design |
677039 |
| 2.5.1.18 | medicine |
dichloroacetate, a degradation product of chloral hydrate, is further metabolized by glutathione transferase zeta 1, and inhibits its own metabolism through depletion/inactivation of GSTZ1/MAAI with repeated exposure, resulting in lower plasma clearance of the drug and the accumulation of the urinary biomarker maleylacetone. The amount of dichloroacetate produced from clinically relevant doses of chloral hydrate, although insufficient to alter dichloroacetate kinetics, is sufficient to inhibit MAAI and tyrosine catabolism |
747644 |
| 2.5.1.18 | medicine |
GSTs catalyzing inactivation of anticancer drugs may find clinical use in protecting sensitive normal tissues to toxic side effects in treated patients, and as selectable markers in gene therapy |
701938 |
